Pharming Group NV announced the appointment of Dr. Perry Calias as the company's Chief Scientific Officer, with immediate effect. Dr. Calias will have overall responsibility for the Company's new Enzyme Replacement Therapy programs, achieving the scientific milestones set in the business plan, enhancing the IP portfolio, overseeing new product development and contributing to the overall strategic direction of the company.